about
Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox-Gastaut syndromeUpdate on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy.Effects of WIN 55,212-2 (a non-selective cannabinoid CB1 and CB 2 receptor agonist) on the protective action of various classical antiepileptic drugs in the mouse 6 Hz psychomotor seizure model.Effect of clobazam as add-on antiepileptic drug in patients with epilepsy.Practice Update: Review of Anticonvulsant Therapy.Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years.Functional characterization of the 1,5-benzodiazepine clobazam and its major active metabolite N-desmethylclobazam at human GABA(A) receptors expressed in Xenopus laevis oocytes.ONe More Weapon in the FIght Against Drop Seizures in Lennox-Gastaut SyndromeClobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studiesExperience in the use of clobazam in the treatment of Lennox-Gastaut syndrome.GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam.Clobazam for treatment of epilepsy.Clobazam for patients with Lennox-Gastaut syndrome and epilepsy.Clobazam : in patients with Lennox-Gastaut syndrome.Clobazam: a newly approved but well-established drug for the treatment of intractable epilepsy syndromes.Clobazam: A Safe, Efficacious, and Newly Rediscovered Therapeutic for Epilepsy.Lennox-Gastaut syndrome. Management update.New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel.Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview.Clobazam as an adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome.Interactions between modulators of the GABA(A) receptor: Stiripentol and benzodiazepinesTreatment of Lennox-Gastaut syndrome: overview and recent findings.Hypothermia associated with clobazam use in adult epilepsyClobazam: An effective add-on therapy in refractory status epilepticus.Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy.Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy
P2860
Q26823805-0A902437-517F-42CF-9BF4-66D4F72315CDQ33664128-52B74F74-0A69-47F0-99A0-5756BC9D1E8BQ33785477-A65AE9A3-98E6-4AF0-A9FA-D8ED91204D0BQ34437102-39C513C8-C0F5-44D1-B164-F25C0376BF21Q34518509-110164E7-D38E-47BC-803D-E457139EB951Q35004437-A66CEE85-E097-4261-BF8A-AB312E2D5220Q35583676-B4F8F648-1526-47CD-8533-B4DD9EAAD86DQ35862637-0BA93BDC-A562-41BF-8E90-A2B409824B0EQ36537180-F2D20A67-796E-4F63-8893-734AF1CD9E6FQ37715506-DF0E87DA-389D-4AE5-BC6F-49765D706D71Q37965230-853D3135-D592-41E5-A65F-E829A9C907ACQ37975516-551990A5-4E0D-4A99-8ADF-2378D0941FF0Q37997090-ED1B5CD3-29C3-404A-AF39-D5E64A861247Q38049247-4A2A6432-7236-4EB9-A280-7CF67D18639AQ38056697-06D0B0FB-541D-432D-9699-75FA25344EF1Q38444948-91E5C480-11AB-4A29-B85C-E8AC73E44850Q38545743-D45A1C0F-4DB1-41B4-8C98-7BA28BD89C2DQ38851234-2D481094-CD53-4BFB-8384-FB3CE48FD583Q39094490-798D365C-AA96-49C6-9A31-4AEF3EAAEB28Q39416423-4880ACEE-3093-40D9-9E23-37823B6806A1Q39607659-07136546-9393-46B4-ADD6-B5BBDC88675CQ39990727-9486AD1D-3F05-48A8-AB17-317014C143DFQ40794125-C668C72F-713C-48D3-9EFE-83EF912B9298Q40950416-DD21B297-9F22-4A28-9580-7F56E1B3B484Q46605318-7CA73316-AA04-46EB-8FB2-FCF6A03C5B7DQ57770173-7FE3B84D-D877-4BB6-ACD4-C29CDE7C23F8
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Clobazam.
@ast
Clobazam.
@en
type
label
Clobazam.
@ast
Clobazam.
@en
prefLabel
Clobazam.
@ast
Clobazam.
@en
P2860
P1433
P1476
Clobazam.
@en
P2093
Stephen D Collins
P2860
P2888
P304
P356
10.1016/J.NURT.2006.11.002
P577
2007-01-01T00:00:00Z
P5875
P6179
1032660334